The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares insights into recent updates made to the response criteria for Waldenström’s macroglobulinemia (WM), highlighting the value of monitoring IgM levels in patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
